{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:57:43Z","timestamp":1788519463761,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":87,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Immunology and Immunopathology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.vetimm.2025.111000","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T11:35:07Z","timestamp":1758022507000},"page":"111000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Engineering an Fc-inert feline IgG1 by targeted mutations: Application to anti-PD-1 antibody development"],"prefix":"10.1016","volume":"288","author":[{"given":"Shoma","family":"Nishibori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiho","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Igase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9580-7557","authenticated-orcid":false,"given":"Takuya","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vetimm.2025.111000_bib1","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.4049\/jimmunol.179.7.4580","article-title":"Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism","volume":"179","author":"Akilesh","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.vetimm.2025.111000_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3604","article-title":"In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy","volume":"9","author":"Arlauckas","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.vetimm.2025.111000_bib3","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.vetimm.2025.111000_bib4","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1158\/1078-0432.CCR-15-1696","article-title":"A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors","volume":"22","author":"Bacac","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.vetimm.2025.111000_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.vetimm.2013.10.018","article-title":"Comparative functional characterization of canine IgG subclasses","volume":"157","author":"Bergeron","year":"2014","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vetimm.2025.111000_bib6","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/intimm\/10.9.1289","article-title":"Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice","volume":"10","author":"Borvak","year":"1998","journal-title":"Int. Immunol."},{"key":"10.1016\/j.vetimm.2025.111000_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12350","article-title":"Mouse and human FcR effector functions","volume":"268","author":"Bruhns","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.vetimm.2025.111000_bib8","first-page":"111","article-title":"Cats, cancer and comparative oncology","volume":"2","author":"Cannon","year":"2015","journal-title":"Vet. Sci."},{"key":"10.1016\/j.vetimm.2025.111000_bib9","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fimmu.2019.00292","article-title":"Fc\u03b3R-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vetimm.2025.111000_bib10","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1080\/19420862.2019.1605270","article-title":"An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans","volume":"11","author":"Chung","year":"2019","journal-title":"MAbs"},{"key":"10.1016\/j.vetimm.2025.111000_bib11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ccell.2015.09.011","article-title":"Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis","volume":"28","author":"Dahan","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.vetimm.2025.111000_bib12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1939-1676.2011.0695.x","article-title":"Mortality in north American dogs from 1984 to 2004: an investigation into age-, size-, and breed-related causes of death","volume":"25","author":"Fleming","year":"2011","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.vetimm.2025.111000_bib13","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/jvim.13985","article-title":"In vitro and in vivo characterization of a fully felinized therapeutic anti-nerve growth factor monoclonal antibody for the treatment of pain in cats","volume":"30","author":"Gearing","year":"2016","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.vetimm.2025.111000_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/jvim.16291","article-title":"Frunevetmab, a felinized anti-nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats","author":"Gruen","year":"2021","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.vetimm.2025.111000_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75533-4","article-title":"A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs","volume":"10","author":"Igase","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.vetimm.2025.111000_bib16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1128\/jvi.4.5.549-553.1969","article-title":"Murine sarcoma and leukemia viruses: assay using clonal lines of contact-inhibited mouse cells","volume":"4","author":"Jainchill","year":"1969","journal-title":"J. Virol."},{"key":"10.1016\/j.vetimm.2025.111000_bib17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1277306","article-title":"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines","volume":"6","author":"Klein","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.vetimm.2025.111000_bib18","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1074\/jbc.M116.767749","article-title":"Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice","volume":"292","author":"Lo","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vetimm.2025.111000_bib19","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.4049\/jimmunol.147.8.2657","article-title":"Human fc gamma RI and fc gamma RII interact with distinct but overlapping sites on human IgG","volume":"147","author":"Lund","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.vetimm.2025.111000_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41698-021-00147-6","article-title":"PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma","volume":"5","author":"Maekawa","year":"2021","journal-title":"NPJ Precis Oncol."},{"key":"10.1016\/j.vetimm.2025.111000_bib21","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1038\/s41598-017-09444-2","article-title":"A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma","volume":"7","author":"Maekawa","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.vetimm.2025.111000_bib22","doi-asserted-by":"crossref","first-page":"6420","DOI":"10.1038\/s41598-023-31543-6","article-title":"Development of anti-feline PD-1 antibody and its functional analysis","volume":"13","author":"Nishibori","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.vetimm.2025.111000_bib23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.vetimm.2025.111000_bib24","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1242\/jcs.115.11.2389","article-title":"beta(2)-Microglobulin is important for cell surface expression and pH-dependent IgG binding of human FcRn","volume":"115","author":"Praetor","year":"2002","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.vetimm.2025.111000_bib25","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3389\/fimmu.2019.01296","article-title":"Conceptual approaches to modulating antibody effector functions and circulation half-life","volume":"10","author":"Saunders","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vetimm.2025.111000_bib26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.vetimm.2025.111000_bib27","article-title":"Optimization of preparation method and specificity verification of cat CD19 monoclonal antibody for disease diagnosis and treatment","volume":"10","author":"Shen","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.vetimm.2025.111000_bib28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.vetimm.2014.01.012","article-title":"In vitro functional characterization of feline IgGs","volume":"158","author":"Strietzel","year":"2014","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vetimm.2025.111000_bib29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/08830189709045703","article-title":"IgG binding sites on human fc gamma receptors","volume":"16","author":"Tamm","year":"1997","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.vetimm.2025.111000_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J."},{"key":"10.1016\/j.vetimm.2025.111000_bib31","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1182\/blood.V87.9.3593.bloodjournal8793593","article-title":"FcR gamma-chain is essential for both surface expression and function of human fc gamma RI (CD64) in vivo","volume":"87","author":"van Vugt","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2025.111000_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.vetimm.2012.08.010","article-title":"Natural killer cells: frequency, phenotype and function in healthy cats","volume":"150","author":"Vermeulen","year":"2012","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vetimm.2025.111000_bib33","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vetimm.2025.111000_bib34","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.vetimm.2025.111000_bib35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13238-017-0473-8","article-title":"IgG fc engineering to modulate antibody effector functions","volume":"9","author":"Wang","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.vetimm.2025.111000_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260954","article-title":"Fc-engineered antibodies with immune effector functions completely abolished","volume":"16","author":"Wilkinson","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.vetimm.2025.111000_bib37","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2287250","article-title":"Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors","volume":"15","author":"Yoshimoto","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.vetimm.2025.111000_bib38","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/jlb.58.4.423","article-title":"Enhanced expression of novel CD57+CD8+ LAK cells from cats infected with feline immunodeficiency virus","volume":"58","author":"Zhao","year":"1995","journal-title":"J. Leukoc. Biol."}],"container-title":["Veterinary Immunology and Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165242725001205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165242725001205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T09:23:56Z","timestamp":1766827436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165242725001205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":38,"alternative-id":["S0165242725001205"],"URL":"https:\/\/doi.org\/10.1016\/j.vetimm.2025.111000","relation":{},"ISSN":["0165-2427"],"issn-type":[{"value":"0165-2427","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering an Fc-inert feline IgG1 by targeted mutations: Application to anti-PD-1 antibody development","name":"articletitle","label":"Article Title"},{"value":"Veterinary Immunology and Immunopathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vetimm.2025.111000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111000"}}